JW gains solid tumor technology license through recent acquisition

By Nikita Chaurasia  | Date: 2020-07-21

JW gains solid tumor technology license through recent acquisition

JW Therapeutics, a biotechnology company headquartered in Shanghai, China, has reportedly acquired Syracuse Biopharma (Hong Kong) Ltd., inclusive of a licensing agreement for Eureka Therapeutics’ solid tumor technology and ARTEMIS® antibody TCR for exclusive use in China and ASEAN nations.

Earlier this month, JW Therapeutics collaborated with Acepodia for the commercialization of two of company’s cell therapy candidates for treating solid tumors and hematologic malignancies.

Dr. James Li, Co-Founder and Head of JW Therapeutics, stated that the company is excited to declare the acquisition of Syracuse for strengthening its clinical expertise in solid tumor cancers. Syracuse and Eureka have devised a unique and effective approach for treating solid tumors with their T-cell receptor antibody mimic antibody (TCRm-Ab) and ARTEMIS® technologies. The company is looking to forward to work with them to deliver the next generation of T cell immunotherapies to patients, he added.

On the other side, Founder and CEO of Eureka Therapeutics, Dr. Cheng Liu is equally excited to work with JW Therapeutics for having recognized the value of the propriety ARTEMIS® platform. With the help of JW, the company is looking to leverage the new-found resources to speed up the development of T cell therapies for its battle against solid tumors.

The number of hepatocellular carcinoma (HCC) cases in China is very high and JW is strategically positioned to develop these therapies and increase its accessibility to patients across China, he added.

Founder and President of Eureka Therapeutics, Dr. Cheng Liu, will now be a part of the Board of Directors at JW Therapeutics, while the Chief Business Officer and General Counsel of Eureka, Victor Shum, will take on the role of a Board Observer, claim credible sources.

The terms of the deal have not been disclosed so far.

Sources: https://www.businesswire.com/news/home/20200720005179/en/JW-Therapeutics-Acquires-Syracuse-Biopharma-License-Eureka

https://www.globenewswire.com/news-release/2020/07/14/2061786/0/en/Acepodia-and-JW-Therapeutics-Enter-into-Option-and-License-Agreement-for-Off-the-shelf-NK-Cell-Therapies.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

By Nikita Chaurasia

Swiftly Systems has reportedly achieved unicorn status, securing in funding through a Series C round. The prominent BRV Capital Management led this funding initiative. According to the earlier reports, Swiftly was adopted by hundreds of consumer b...

Rainforest nations unify to demand cash for climate & biodiversity preservation

Rainforest nations unify to demand cash for climate & biodiversity preservation

By Nikita Chaurasia

As per the reports, twelve nations with rainforests united to establish a collective initiative aiming to address climate change and safeguard biodiversity at summit held in Brazil. The declaration, titled "United for Our Forests," emerged ...

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

By Nikita Chaurasia

Meta Platforms has recently introduced Llama 2, an artificial intelligence large language model, for commercial use in collaboration with major cloud providers like Microsoft. Instead of charging for access or usage, Meta aims to share the model with...

Moderna signs agreement to explore mRNA medicines in China

Moderna signs agreement to explore mRNA medicines in China

By Nikita Chaurasia

Moderna Inc, a leading vaccine manufacturer, reportedly announced on Wednesday that it has entered into a memorandum of understanding (MoU) and a land collaboration agreement aimed at exploring opportunities for researching, developing, and producing...

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

By Nikita Chaurasia

The American footwear design & manufacturing company, Nike and Epic Games, the creators of the popular online game Fortnite, have joined forces in an exciting new collaboration. The partnership aims to bring about a groundbreaking change in the d...